Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaojing, Ren, Hanru, Xu, Yi, Peng, Xue, Yu, Wenxi, Shen, Zan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841677/
https://www.ncbi.nlm.nih.gov/pubmed/36642742
http://dx.doi.org/10.1186/s40001-022-00894-7
_version_ 1784869907307954176
author Yang, Xiaojing
Ren, Hanru
Xu, Yi
Peng, Xue
Yu, Wenxi
Shen, Zan
author_facet Yang, Xiaojing
Ren, Hanru
Xu, Yi
Peng, Xue
Yu, Wenxi
Shen, Zan
author_sort Yang, Xiaojing
collection PubMed
description Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.
format Online
Article
Text
id pubmed-9841677
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98416772023-01-17 Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases Yang, Xiaojing Ren, Hanru Xu, Yi Peng, Xue Yu, Wenxi Shen, Zan Eur J Med Res Review Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases. BioMed Central 2023-01-16 /pmc/articles/PMC9841677/ /pubmed/36642742 http://dx.doi.org/10.1186/s40001-022-00894-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yang, Xiaojing
Ren, Hanru
Xu, Yi
Peng, Xue
Yu, Wenxi
Shen, Zan
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title_full Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title_fullStr Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title_full_unstemmed Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title_short Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
title_sort combination of radiotherapy and targeted therapy for her2-positive breast cancer brain metastases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841677/
https://www.ncbi.nlm.nih.gov/pubmed/36642742
http://dx.doi.org/10.1186/s40001-022-00894-7
work_keys_str_mv AT yangxiaojing combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases
AT renhanru combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases
AT xuyi combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases
AT pengxue combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases
AT yuwenxi combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases
AT shenzan combinationofradiotherapyandtargetedtherapyforher2positivebreastcancerbrainmetastases

Ejemplares similares